Pain experience of patients with heart failure has not been described insufficient detail. This study sampled patients hospitalized with HF to describe the prevalence and severity of pain. 85% of the patients reported pain and 42.5% said it was in the severe or very severe range.
Pain experience of patients with heart failure has not been described insufficient detail. This study sampled patients hospitalized with HF to describe the prevalence and severity of pain. 85% of the patients reported pain and 42.5% said it was in the severe or very severe range.
Pain experience of patients with heart failure has not been described insufficient detail. This study sampled patients hospitalized with HF to describe the prevalence and severity of pain. 85% of the patients reported pain and 42.5% said it was in the severe or very severe range.
Patients with Heart Failure Tone Rusten, RN, PhD, Audun Stubhaug, MD, PhD, Ingrid Eidsmo, RN, Arne Westheim, MD, PhD, Steven M. Paul, PhD, and Christine Miaskowski, RN, PhD Faculty of Nursing (T.R., A.S.), Oslo University College, Oslo; Centre for Shared Decision Making and Nursing Research (T.R., C.M.) and Department of Anesthesia (A.S.), Rikshospitalet University Hospital, Oslo; and Ullevaal University Hospital (I.E., A.W.), Oslo, Norway; and Department of Physiological Nursing (S.M.P., C.M.), University of California at San Francisco, San Francisco, California, USA Abstract The pain experience of patients with heart failure (HF) and its impact on their quality of life (QOL) has not beendescribed insufcient detail. This study sampled patients hospitalized with HF to describe the prevalence and severity of bodily pain; evaluate differences in bodily pain related to selected demographic and disease-specic characteristics; and evaluate the effect of selected demographic, disease-specic characteristics, bodily pain, and mental health on QOL. Two items from the Medical Outcomes StudydShort Form (SF-36) were used to measure pain, and one subscale of the SF-36 was used to evaluate mental health. The Minnesota Living With Heart Failure Questionnaire was used to measure QOL. Patients with HF (n 93) had a mean age of 75 years, were predominantly male (65%), and lived alone (47.3%). Lung diseases and diabetes were the most common comorbidities; 58% were categorized as New York Heart Association(NYHA) Class III, whereas 58%of the sample was diagnosed with HF inthe past four years. Of note, 85% of the patients reported pain and 42.5% said that it was in the severe or very severe range. No demographic variables were associated with pain, whereas a higher number of chronic conditions were associated with pain. SF-36 mental health and pain scores, as well as NYHA class, explained 34.1% of the variance in QOL in patients with HF. These data suggest that pain is highly prevalent and has a signicant impact on the QOL of patients with HF. However, additional research is warranted to determine the specic causes and characteristics of pain in these patients. J Pain Symptom Manage 2008;36:497e504. 2008 U.S. Cancer PainRelief Committee. Published by Elsevier Inc. All rights reserved. This study took place at Ullevaal University Hospital and Buskerud Hospital Trust and was funded by Oslo University College. The data fromthe general population applied in this publication are based on the Survey of Level of Living 2002 in Norway. Deidentied date sets have been made available by the Norwegian Social Sci- ence Data Services (NSD). Statistics Norway (SSB) was responsible for sampling and interviewing. Neither NSD nor SSB are responsible for the analy- ses/interpretation of data presented here. Address correspondence to: Tone Rusten, RN, PhD, Faculty of Nursing, Oslo University College, Postbox 4, St. Olavs Place, 0131 Oslo, Norway. E-mail: tone.rustoen@su.hio.no Accepted for publication: December 4, 2007. 2008 U.S. Cancer Pain Relief Committee Published by Elsevier Inc. All rights reserved. 0885-3924/08/$esee front matter doi:10.1016/j.jpainsymman.2007.11.014 Vol. 36 No. 5 November 2008 Journal of Pain and Symptom Management 497 Key Words Quality of life, pain, congestive heart failure Introduction Heart failure (HF) has become one of the most important chronic medical conditions worldwide. 1,2 The clinical course of HF is char- acterized by acute exacerbations that require emergency department visits or hospitaliza- tions followed by periods of stable disease. HF is a chronic medical condition that affects all aspects of patients lives and has a tremen- dous impact on quality of life (QOL). 3,4 Stud- ies have shown that patients with HF report a poorer QOL when compared to the general population. 5e8 In most of these studies, which used either a disease-specic instrument or a general QOL questionnaire, patients with HF reported lower scores in all domains of QOL (e.g., lower levels of physical functioning, and worse mental health). In addition, pa- tients with HF compared to the general popu- lation 5 reported signicant limitations in mobility and self-care activities. Most recently, scores on a disease-specic measure of QOL were shown to be strongly associated with de- creased survival in patients with HF. 9 Several studies 5,10e14 have found that a vari- ety of symptoms are associated with decreases in QOL in patients with HF. For example, Cal- vert et al. 5 found that pain, anxiety, and depres- sion were associated with decreased QOL. In this study, 68% of patients with HF reported pain/discomfort, compared to only 33% of the general population. Goodlin et al. 11 found that the most common causes of symptom dis- tress in advanced HF were lack of energy, weak- ness or fatigue, pain, dyspnea, insomnia, and depression. In addition, Levenson et al. 14 found that the percentage of patients with HF with severe pain increased signicantly during the last six months of life. Finally, in a study by Sullivan and OMeara, 13 patients who died from cardiovascular disease with concomitant HF reported signicantly more symptoms, in- cluding chest and abdominal pain, worse func- tional status, and poorer self-rated health near the end of life than patients who died from cardiovascular disease alone. A recent systematic review on the symptom of pain with HF 15 found only nine studies that reported minimal data on pain in these patients. In the ve studies that reported data specically on patients with HF, the prev- alence of pain ranged from 23% to 75%. In a more recent study of outpatients with chronic HF, 16 52% reported pain and 42% cat- egorized it as extremely distressing. However, data on pain prevalence were obtained using dichotomous yes/no questions or researcher- developed single items, and not with a validated pain measure. None of these studies reported on the severity of pain or on the level of inter- ference of pain with activities. Although recent data suggest that pain oc- curs in a signicant percentage of patients with HF and that pain and other symptoms are associated with decreases in QOL in this population, additional studies are warranted to determine the prevalence and severity of pain; factors associated with increased pain; and the impact of pain on QOL in patients with HF. Therefore, the purposes of this study, in a sample of patients who were hospitalized for HF, were to describe the prevalence and se- verity of bodily pain; evaluate for differences in bodily pain related to selected demographic and disease-specic characteristics; and evalu- ate the effects of selected demographic (e.g., age, gender, and living situation) and disease- specic (e.g., ejection fraction [EF]) character- istics, bodily pain, and mental health on QOL. Materials and Methods Participants and Data Collection Procedures This study was part of a larger descriptive study that evaluated the relationship between hope and QOL in patients with HF. Patients were diagnosed with HF using the 1995 Euro- pean Society of Cardiology Criteria for HF. 17 Pa- tients were recruited from two acute care hospitals in Norway. Consecutive patients, who were hospitalized for HF over a period of 24 months and met the studys inclusion criteria, were askedto participate several days after admis- sion to the hospital, when their condition had stabilized. Patients were included if they were able to read and write Norwegian and had 498 Vol. 36 No. 5 November 2008 Rusten et al. a normal mental status as judged by the nurse who was caring for the patients. The main rea- sons why patients declined to participate were previous involvement in another research study or severe fatigue. This study was approved by the Norwegian Committee onHuman Research. All patients signed a written informed consent before participation in the study. Instruments Demographic Characteristics. Data on age, gen- der, marital status, living situation, and educa- tional level were obtained for all patients. Marital status was categorized as married or not married (i.e., widowed, divorced, or not married). Living situation was categorized as living with spouse/another adult or children, or living alone. Educational level was catego- rized as primary school, secondary school, or university/college education. Comorbidities and Disease-Specic Characteristics. Patients were asked if they currently had or had a history of cancer; diabetes; musculoskeletal, skin, lung, or gastrointestinal diseases; or psy- chiatric disorders. Lengthof time since HFdiag- nosis, New York Heart Association (NYHA) classication, EF value, and medications were obtained from the medical record. EF values were categorized as preserved left ventricular systolic function (EF >40%) or reduced left ventricular systolic function (EF #40%). 18 Pain. Two items from the Medical Outcomes StudydShort Form (SF-36) were used to mea- sure pain. The SF-36 consists of 36 items of self-reported aspects of health. 19e22 The Nor- wegian version of the SF-36 has acceptable psy- chometric properties. 23e25 The rst pain question asks, How much bodily pain have you had during the past 4 weeks? The responses are none, very mild, mild, moderate, severe, or very severe. The second question asks, During the past 4 weeks, how much did pain interfere with your normal work (including both work outside the home and housework)? The choices are not at all, a little bit, moder- ately, quite a bit, or extremely. The responses to the rst item were used to deter- mine pain prevalence and severity. Responses to the second item were used to determine pain interference. For the various correlational analyses, the two pain items were summarized into a subscale of the SF-36 called bodily pain, with scores that could range from 0 to 100, and with lower scores indicating more pain. Mental Health. The mental health subscale of the SF-36 was used to evaluate the impact of anxiety and depression on pain and QOL. Quality of Life. The Minnesota Living with Heart Failure Questionnaire (MLHFQ) was used to measure QOL because it is a disease- specic QOL questionnaire. This 21-item ques- tionnaire measures patients perceptions of the effects of HF on life satisfaction. 26e28 Pa- tients were asked to rank how each of the im- pairments associated with HF prevented them from living as they wanted to live. Each item is scored on a Likert scale that ranges from 0 (no) to 5 (very much). Individual items are summed to create two subscale scores (i.e., emotional and physical) and a total score that can range from 0 to 105. Lower subscale and total scores indicate a better QOL. The MLHFQ has demonstrated adequate validity and reliability internationally, 29,30 but had not been used in a Norwegian sample before this study. It was translated into Norwegian us- ing the forward and backward procedure. 31 In this study, the Cronbachs alpha for the total score was 0.88. Statistical Analyses Data were analyzed using SPSS Version 14.0 (Chicago, IL). Descriptive statistics were gener- ated to characterize the sample, the preva- lence, and severity of bodily pain. One-way analyses of variance and Chi- squared analyses were performed to evaluate differences in SF-36 bodily pain and QOL scores using select demographic (i.e., age cate- gory, gender, education level, marital status, and cohabitation [yes, no]) and disease- specic characteristics (i.e., NYHA class, EF value, and different chronic diseases [yes, no]). To determine the variables to include in the subsequent multiple regression analysis to pre- dict QOL (i.e., total score on the MLHFQ), cor- relation coefcients were calculated between the total QOL score and selected demographic and disease-specic characteristics, as well as SF-36 bodily pain and mental health scores. A Vol. 36 No. 5 November 2008 499 Pain and QOL in HF multiple regression analysis was performed to determine the effects of the signicant vari- ables from the univariate analyses on QOL. All signicant variables from the univariate analyses were entered into the model simulta- neously. To construct a model that was parsimo- nious, variables were systematically removed until only signicant predictors remained in the nal model. For all tests, a P-value of <0.05 was considered statistically signicant. Results Demographic Characteristics Ninety-three patients with HF were recruited for this study. As shown in Table 1, the mean age was 75.1 years (SD9.7 years) and 64.5% of the patients were male. Almost half of the sample lived alone, 20.7% had a college or university education, and 44.6% were mar- ried. Approximately 85% of the patients were either disabled or retired. Characteristics of HF and Previous and Concurrent Medical Conditions More than half of the sample (58%) was di- agnosed with HF in the past four years. Most patients (81%) were classied as NYHA Class III or IV and 68.1% had reduced left ventricu- lar systolic function with EF values #40% (Table 1). The mean EF for the patients was 34.5% (SD12.3%). As many as 80% of the patients reported hav- ing one or more chronic conditions in addition to HF. The most common comorbidities were lung disease (31.2%), diabetes (30.1%), muscu- loskeletal disease (21.5%), cancer (16.1%), skin disease (15.1%), gastrointestinal disease (14.0%), and psychiatric disorders (4.3%). In addition to HF, one condition was reported by 47.3% of the patients, two by 16.1%, three by 12.9%, and four or ve by 3.3% of the patients. Data on medications were collected for 78 (83.9%) of the patients. While in the hospital, patients were taking an average of seven med- ications (SD2.5, range 2e14) for HF, other medical conditions, and pain. Of note, only one of 78 patients were taking nonsteroidal anti-inammatory drugs, two of 78 were taking paracetamol (acetaminophen) plus an opioid, 11 of 78 were taking steroids, two of 78 were taking opioids, and eight of 78 patients were taking antidepressants. In addition, patients were prescribed low-dose aspirin (26 of 78) as treatment for coronary heart disease (CHD); long-acting nitroglycerin (21 of 78) and nitroglycerine patches (ve of 78) for HF or CHD; and nitroglycerine sublingual (two of 78) for CHD-related chest pain. Pain Prevalence, Severity, and Interference Based on the SF-36 item bodily pain in last 4 weeks, 85%of the 87patients withHF(n 74), who answered this question, reported some pain. A total of 13 patients (14.9%) reported none, eight (9.2%) reported very mild pain, six (6.9%) reported mild pain, 23 (26.4%) reported moderate pain, 28 (32.2%) reported severe pain, and nine (10.3%) reported very severe pain. On the pain interference with normal work item, of the 87 patients with HF who answered this question, 19 patients (21.8%) re- ported not at all, 11 (12.6%) reported a little bit, 17 (19.5%) reported moderately, 20 (23.0%) reported quite a bit, and 20 (23.0%) reported extremely. The mean SF-36 bodily pain score for this sample was 43.0 (SD30.1, range 0e100), with lower scores indicating higher levels of bodily pain. Table 1 Demographic and Disease-Specic Characteristics of the Patients with HF Characteristics n (%) Age (years) [mean (SD) range] 75.1 (9.7) 48e93 Gender Male 60 (64.5) Female 33 (35.5) Living situation Alone 43 (47.3) Spouse/children 48 (52.7) Marital status Married 41 (44.6) Not married 51 (55.4) Education Primary school 40 (46.0) Secondary school 29 (33.3) University/college 18 (20.7) NYHA Class I 2 (2.3) II 14 (16.7) III 47 (56.0) IV 21 (25.0) EF value [mean (SD) range] 34.5 (12.3) 7%e73% #40% 47 (68.1) >40% 22 (31.9) 500 Vol. 36 No. 5 November 2008 Rusten et al. Differences in SF-36 Bodily Pain Scores With respect to demographic characteristics, no differences in mean SF-36 bodily pain scores were found based on age, gender, mari- tal status, cohabitation, or educational level. With respect to disease-specic characteristics, no differences were found in mean SF-36 bodily pain scores based on NYHA class, EF values, or presence of various chronic medical conditions. However, a signicant negative cor- relation was found between mean SF-36 bodily pain score and number of chronic conditions (r 0.21; P 0.045), which suggests that a higher number of chronic conditions was associated with more pain. Differences in QOL Scores Eighty-three patients completed the MLHFQ. The mean QOL score was 54.7 (SD21.5). QOL scores ranged from a low of 6.0 to a high of 95.1. With respect to demographic character- istics, no differences in mean QOL scores were found based on age, gender, marital status, cohabitation, or educational level. With respect to disease-specic characteristics, a signicant negative correlation was found between the patients EF values and total QOL scores (r 0.27, P 0.03). In addition, signicant differences in total QOL scores were found among the four NYHA classes (F 3,70 3.3, P 0.025). Post hoc contrasts demonstrated that the patients in NYHA Class IV had signi- cantly higher mean QOL scores (i.e., worse QOL) thanpatients inNYHAClass II (P 0.023). Effect of Selected Demographic and Disease- Specic Characteristics, Bodily Pain, and Mental Health on QOL Table 2 lists the univariate correlations between the total score on the MLHFQ and selected demographic and disease-specic characteristics, as well as SF-36 bodily pain and mental health scores. Based on the nd- ings from these correlational analyses, a multi- ple regression analysis was performed using SF-36 mental health, bodily pain scores, and NYHA class as predictors of QOL. As shown in Table 3, the overall model explained 34.1% of the variance in QOL, using the total score from the MLHFQ as the dependent vari- able (P <0.001). In terms of unique contribu- tions, mental health explained 9% of the variance (P 0.005), NYHA class explained 7% of the variance (P 0.008), and pain ex- plained 5% of the variance (P 0.03) in QOL. Discussion This study is the rst to evaluate the preva- lence and severity of pain in a sample of hospi- talized patients with HF using a validated pain measure and to examine the relationships be- tweenvarious demographic anddisease-specic characteristics, as well as pain, on patients QOL. Of note, 85% of the patients with HF re- ported some level of pain and 42.5% reported pain in the severe to very severe range. To place these ndings on pain prevalence and severity in patients with HF into context, they were com- pared with pain prevalence and pain severity rates reported by a sample drawn from the Nor- wegian general population. 32 Using responses from the SF-36, approximately 70% of the Nor- wegiangeneral populationreported some pain. However, only 13% reported that their pain was in the severe to very severe range. In addition, whereas 80% of the patients with HF reported that pain interfered with their normal work, only 50% of the sample from the general popu- lationreportedthis nding. These comparisons suggest that pain is a signicant problem for patients with HF. The overall percentage of patients with HF in pain in this study is somewhat higher than Table 2 Relationships Between Total Scores on the MLHFQ and Selected Demographic, Clinical, and Miscellaneous Characteristics Characteristics Total Score on the MLHFQ r P-value Demographic characteristics Age 0.09 0.44 Gender 0.19 0.08 Living situation 0.12 0.27 Marital status 0.14 0.20 Education 0.20 0.08 Clinical characteristics NYHA class 0.31 0.01 EF value L0.27 0.03 Total number of diseases 0.06 0.63 Miscellaneous characteristics Mental health L0.51 <0.0001 Bodily pain L0.46 <0.0001 Values in bold are statistically signicant at the 0.05 level. Vol. 36 No. 5 November 2008 501 Pain and QOL in HF the range of 23% to 75% reported in the re- view by Godfrey et al. 15 This difference may be attributed to the fact that patients with HF in this study were hospitalized with an exacer- bation of their HF. It is interesting to note that the prevalence rates and severity ratings of pain in this sample of patients with HF are comparable to those reported by patients with breast and lung cancer pain. 33,34 How- ever, the bodily pain scores (43.0 30.1) of pa- tients with HF are lower than those reported by patients with chronic pain who were admit- ted to a pain center (i.e., 26.0 16.0). 35 Despite the high prevalence rates and sever- ity scores across a number of studies, 5,11,13e16 the paucity of research on pain in patients with HF makes it difcult to draw denitive conclusions about the causes and characteris- tics of the pain. In one study of patients with HF, 12 53.7% reported chest pain, whereas 57.4% reported pain from other causes. In an- other study, 13 22%e37% of patients reported chest pain and 12%e18% reported abdominal pain. However, one can hypothesize that given the number of comorbid conditions that pa- tients with HF have, as well as the fatigue and deconditioning that occurs with HF, 16,36 pain could occur from a variety of conditions or problems. Therefore, additional research with pain-specic measures (e.g., Brief Pain Inventory 37 and McGill Pain Questionnaire 38 ) is needed to determine the specic etiologies for the pain reported by patients with HF. It is interesting to note that no differences were found in the mean SF-36 bodily pain scores based on selected demographic (i.e., age, gender, marital status, cohabitation, or ed- ucational level) or disease-specic (i.e., NYHA class, EF values, or presence of various chronic medical conditions) characteristics. These ndings are in contrast with previous studies of differences in pain intensity among the Norwegian population based on age, 39 gen- der, 40 or the presence of a chronic illness. 41 These inconsistent ndings may be partially explained by the relatively small sample size of patients with HF in this study. Several studies have evaluated the impact of HF on patients QOL. 5,7e9,12,16,42,43 Consistent with the ndings from this study, previous studies 5,7e9,42 have demonstrated that worsen- ing HF, as measured by NYHA class, was associ- ated with a poorer QOL. In addition, as was seen in this study, higher levels of depression were associated with poorer QOL. 42 It is not readily apparent why older age and female gender were not associated with decreases in QOL that were reported in previous studies. 30,42 Possible explanations for these differences are the higher percentage of men and the older age of the participants in this study. This study is the rst to demonstrate that, in conjunction with severity of disease and worse mental health, pain has a negative impact on QOL and uniquely explains 5% of the variance in QOL in patients with HF. Perhaps this association was not made previously because although the two most commonly used dis- ease-specic measures of QOL for patients with HF (i.e., MLHFQ and Kansas City Cardio- myopathy Questionnaire) do evaluate other symptoms (e.g., dyspnea and fatigue), neither includes a pain item. However, one needs to acknowledge that only 34.1% of the variance in QOL was ex- plained by this model and that pains unique contribution to the percent of explained vari- ance was only 5%. These ndings suggest that either the relatively small sample size or other factors not measured in this study con- tribute to the variance in QOL in patients with HF. For example, in a recent study of 2709 patients with HF, 44 independent factors associated with poorer QOL were female Table 3 Effect of Bodily Pain, Mental Health, and Severity of the Disease on QOL in Patients with HF (Multiple Regression Summary; Dependent Variable: QOL [total score on the MLHFQ] n 70) Source R 2 r b R 2 -Change df F P Overall model 0.341 3,66 11.38 <0.001 Mental health 0.48 a 0.32 0.09 1,66 8.50 0.005 NYHA class 0.35 b 0.28 0.07 1,66 7.43 0.008 Bodily pain 0.37 c 0.25 0.05 1,66 50.90 0.027 a Zero order correlation is signicant at the P <0.0001 level. b Zero order correlation is signicant at the 0.002 level. c Zero order correlation is signicant at the 0.001 level. 502 Vol. 36 No. 5 November 2008 Rusten et al. gender, younger age, higher body mass index, lower systolic blood pressure, greater symptom burden, and worse functional status. In an- other study of 60 outpatients with HF, 16 depression was associated with a greater num- ber of symptoms, which in turn was associated with decreased QOL. Finally, Zambroski et al., 12 in a convenience sample of 53 outpa- tients with HF, found that younger age, worse functional status, higher symptom prevalence, and higher symptom burden were associated with decreased QOL. Although ndings from these three studies 12,16,44 suggest that symp- tom burden has a negative impact on the QOL of patients with HF, none of these studies evaluated the independent effect of pain on QOL. Additional research is warranted to eval- uate the independent contribution of the most common symptoms on the QOL of patients with HF. In addition, the effect of other fac- tors, such as social support and coping strate- gies, on QOL need to be evaluated in future research studies. Several limitations of this study are worth noting. Because the primary purpose of this study was to evaluate the relationship between hope and QOL in patients with HF, a detailed pain questionnaire was not administered to the participants. Therefore, little is known about the causes and characteristics of pain in this sample. In addition, because of the rel- atively small sample size that is primarily male and older, denitive conclusions cannot be made about the inuence of gender and age on the pain experience of patients with HF. Despite its limitations, the ndings from this study provide evidence that unrelieved pain is a signicant problem for patients with HF. In addition, as with other chronic medical condi- tions, unrelieved pain has a negative impact on patients QOL. These ndings point to the need for additional studies to characterize the problem of chronic pain in patients with HF. Without specic epidemiologic data, the development of appropriate interventions for pain in this population will not occur. References 1. McCullough PA, Philbin EF, Spertus JA, et al. Conrmation of a heart failure epidemic: ndings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol 2002;39:60e69. 2. Remme WJ, McMurray JJ, Rauch B, et al. Public awareness of heart failure in Europe: rst results from SHAPE. Eur Heart J 2005;26:2413e2421. 3. Johansson P, Agnebrink M, Dahlstrom U, Brostrom A. Measurement of health-related quality of life in chronic heart failure, from a nursing per- spectiveda review of the literature. Eur J Cardiovasc Nurs 2004;3:7e20. 4. Johansson P, Dahlstrom U, Brostrom A. The measurement and prevalence of depression in pa- tients with chronic heart failure. Prog Cardiovasc Nurs 2006;21:28e36. 5. Calvert MJ, Freemantle N, Cleland JG. The im- pact of chronic heart failure on health-related qual- ity of life data acquired in the baseline phase of the CARE-HF study. Eur J Heart Fail 2005;7:243e251. 6. Ekman I, Fagerberg B, Lundman B. Health- related quality of life and sense of coherence among elderly patients with severe chronic heart failure in comparison with healthy controls. Heart Lung 2002;31:94e101. 7. Hobbs FD, Kenkre JE, Roalfe AK, et al. Impact of heart failure and left ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population. Eur Heart J 2002;23:1867e1876. 8. Juenger J, Schellberg D, Kraemer S, et al. Health related quality of life in patients with conges- tive heart failure: comparison with other chronic diseases and relation to functional variables. Heart 2002;87:235e241. 9. Sullivan MD, Levy WC, Russo JE, Crane B, Spertus JA. Summary health status measures in advanced heart failure: relationship to clinical vari- ables and outcome. J Card Fail 2007;13:560e568. 10. Ekman I, Cleland JG, Andersson B, Swedberg K. Exploring symptoms in chronic heart failure. Eur J Heart Fail 2005;7:699e703. 11. Goodlin SJ, Hauptman PJ, Arnold R, et al. Con- sensus statement: palliative and supportive care in advanced heart failure. J Card Fail 2004;10:200e209. 12. Zambroski CH, Moser DK, Bhat G, Ziegler C. Impact of symptom prevalence and symptom bur- den on quality of life in patients with heart failure. Eur J Cardiovasc Nurs 2005;4:198e206. 13. Sullivan MD, OMeara ES. Heart failure at the end of life: symptoms, function, and medical care in the Cardiovascular Health Study. Am J Geriatr Cardiol 2006;15:217e225. 14. Levenson JW, McCarthy EP, Lynn J, Davis RB, Phillips RS. The last six months of life for patients with congestive heart failure. J Am Geriatr Soc 2000;48:S101eS109. 15. Godfrey C, Harrison MB, Medves J, Tranmer JE. The symptom of pain with heart failure: a systematic review. J Card Fail 2006;12:307e313. Vol. 36 No. 5 November 2008 503 Pain and QOL in HF 16. Bekelman DB, Havranek EP, Becker DM, et al. Symptoms, depression, and quality of life in patients with heart failure. J Card Fail 2007;13:643e648. 17. Remme WJ, Swedberg K. Guidelines for the di- agnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527e1560. 18. Persson H, Lonn E, Edner M, et al. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence: results from theCHARMEchocardiographicSubstudy-CHARMES. J Am Coll Cardiol 2007;49:687e694. 19. Ware JE Jr. SF-36 health survey update. Spine 2000;25:3130e3139. 20. WareJE, Kosinski M. InterpretingSF-36 summary health measures: a response. Qual Life Res 2001;10: 405e413; discussion 415e420. 21. Ware JE Jr, Kosinski M, Gandek B, et al. The fac- tor structure of the SF-36 Health Survey in 10 coun- tries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 1998; 51:1159e1165. 22. Ware JE Jr, Sherbourne CD. The MOS 36-item short-formhealthsurvey (SF-36). I. Conceptual frame- work and item selection. Med Care 1992;30:473e483. 23. Flaatten H, Kvale R. Survival and quality of life 12 years after ICU. A comparison with the general Norwegian population. Intensive Care Med 2001; 27:1005e1011. 24. Kvien TK, Kaasa S, Smedstad LM. Performance of the Norwegian SF-36 Health Survey in patients with rheumatoid arthritis. II. A comparison of the SF-36 with disease-specic measures. J Clin Epide- miol 1998;51:1077e1086. 25. Loge JH, Kaasa S, Hjermstad MJ, Kvien TK. Translation and performance of the Norwegian SF-36 Health Survey in patients with rheumatoid arthritis. I. Data quality, scaling assumptions, reli- ability, and construct validity. J Clin Epidemiol 1998; 51:1069e1076. 26. Rector TS, Tschumperlin LK, Kubo SH, et al. Use of the Living With Heart Failure questionnaire to ascertain patients perspectives on improvement in quality of life versus risk of drug-induced death. J Card Fail 1995;1:201e206. 27. Rector T, Kubo S, Cohn J. Patients self-assess- ment of their congestive heart failure. Part 2: Con- tent, reliability, and validity of a new measure, the Minnesota Living With Heart Failure Questionnaire. Heart Fail 1987 Oct/Nov;198e210. 28. Rector TS, Kubo SH, Cohn JN. Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo. Am J Cardiol 1993;71:1106e1107. 29. Riegel B, Moser DK, Glaser D, et al. The Minneso- ta Living With Heart Failure Questionnaire: sensitiv- ity to differences and responsiveness to intervention intensity in a clinical population. Nurs Res 2002;51: 209e218. 30. Heo S, Moser DK, Riegel B, Hall LA, Christman N. Testing the psychometric properties of the Minnesota Living with Heart Failure ques- tionnaire. Nurs Res 2005;54:265e272. 31. Guillemin F, Bombardier C, Beaton D. Cross-- cultural adaptation of health-related quality of life measures: literature review and proposed guide- lines. J Clin Epidemiol 1993;46:1417e1432. 32. Hougen HC, Globoden MA. Coordinated survey of living conditions 2002dpanel survey. Dokumentas- jonsrapport. [Stat Norway (Norwegian)] 2004;1e108. 33. Velanovich V, Szymanski W. Quality of life of breast cancer patients with lymphedema. Am J Surg 1999;177:184e187. 34. Handy JR Jr, Asaph JW, Skokan L, et al. What happens to patients undergoing lung cancer sur- gery? Outcomes and quality of life before and after surgery. Chest 2002;122:21e30. 35. Fredheim OM, Borchgrevink PC, Saltnes T, Kaasa S. Validation and comparison of the health- related quality-of-life instruments EORTC QLQ-C30 and SF-36 in assessment of patients with chronic nonmalignant pain. J Pain Symptom Manage 2007; 34(6):657e665. 36. Ekman I, Cleland JG, Swedberg K, et al. Symp- toms in patients with heart failure are prognostic predictors: insights from COMET. J Card Fail 2005;11:288e292. 37. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Sin- gap 1994;23:129e138. 38. Melzack R. The McGill Pain Questionnaire: ma- jor properties and scoring methods. Pain 1975;1: 277e299. 39. Rustoen T, Wahl AK, Hanestad BR, et al. Age and the experience of chronic pain: differences in health and quality of life among younger, middle-- aged, and older adults. Clin J Pain 2005;21: 513e523. 40. Rustoen T, Wahl AK, Hanestad BR, et al. Gender differences in chronic paindndings from a population-based study of Norwegian adults. Pain Manag Nurs 2004;5:105e117. 41. Rustoen T, Wahl AK, Hanestad BR, et al. Preva- lenceandcharacteristics of chronicpaininthegeneral Norwegian population. Eur J Pain 2004;8:555e565. 42. Gott M, Barnes S, Parker C, et al. Predictors of the quality of life of older people with heart failure recruited from primary care. Age Ageing 2006;35: 172e177. 43. HouN, Chui MA, Eckert GJ, et al. Relationshipof age and sex to health-related quality of life inpatients with heart failure. Am J Crit Care 2004;13:153e161. 44. Lewis EF, Lamas GA, OMeara E, et al. Charac- terization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. Eur J Heart Fail 2007;9:83e91. 504 Vol. 36 No. 5 November 2008 Rusten et al.